Brief: Cue Biopharma Reports Two Objective Responses (1 Cpr And 1Upr) In First Interim Update From Dose Escalation Portion Of Ongoing Phase 1 Combination Study Of Cue-101 And Keytruda® In First Line Patients With Hpv+ Recurrent/Metastatic Head And Neck Cancer

Cue Biopharma

26/01/2022 22:07

Jan 26 (Reuters) - Cue Biopharma Inc  CUE.O :
    * CUE BIOPHARMA REPORTS TWO OBJECTIVE RESPONSES (1 CPR AND
1UPR)
IN FIRST INTERIM UPDATE FROM DOSE ESCALATION PORTION OF ONGOING
PHASE 1 COMBINATION STUDY OF CUE-101 AND KEYTRUDA® IN FIRST LINE
PATIENTS WITH HPV+ RECURRENT/METASTATIC HEAD AND NECK CANCER
    * CUE BIOPHARMA INC - EARLY DATA IN COMBINATION STUDY OF
CUE-101
AND KEYTRUDA (PEMBROLIZUMAB) SUPPORTS SYNERGISTIC ACTIVITY
    * CUE BIOPHARMA INC - UPDATED CUE-101 MONOTHERAPY DATA
FURTHER
ENHANCES CONFIDENCE IN POTENTIAL AS SINGLE AGENT THERAPEUTIC

Source text for Eikon:  ID:nGNX5fk6nk 
Further company coverage:  CUE.O 

 ((Reuters.Briefs@thomsonreuters.com;))